[go: up one dir, main page]

WO2003074663A3 - MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE - Google Patents

MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE Download PDF

Info

Publication number
WO2003074663A3
WO2003074663A3 PCT/US2003/006088 US0306088W WO03074663A3 WO 2003074663 A3 WO2003074663 A3 WO 2003074663A3 US 0306088 W US0306088 W US 0306088W WO 03074663 A3 WO03074663 A3 WO 03074663A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
mp21s
modifiers
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/006088
Other languages
French (fr)
Other versions
WO2003074663A2 (en
Inventor
Marcia Belvin
Lori Friedman
Gregory D Plowman
Timothy S Heuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to AU2003223208A priority Critical patent/AU2003223208A1/en
Publication of WO2003074663A2 publication Critical patent/WO2003074663A2/en
Publication of WO2003074663A3 publication Critical patent/WO2003074663A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human MP21 genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of MP21 are provided.
PCT/US2003/006088 2002-03-01 2003-02-28 MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE Ceased WO2003074663A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003223208A AU2003223208A1 (en) 2002-03-01 2003-02-28 MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36082502P 2002-03-01 2002-03-01
US36075902P 2002-03-01 2002-03-01
US60/360,759 2002-03-01
US60/360,825 2002-03-01

Publications (2)

Publication Number Publication Date
WO2003074663A2 WO2003074663A2 (en) 2003-09-12
WO2003074663A3 true WO2003074663A3 (en) 2004-03-25

Family

ID=27791653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006088 Ceased WO2003074663A2 (en) 2002-03-01 2003-02-28 MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2003223208A1 (en)
WO (1) WO2003074663A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958697A (en) * 1997-12-08 1999-09-28 Tularik Inc. Isolated nucleic acids encoding CYP7 promoter-binding factors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958697A (en) * 1997-12-08 1999-09-28 Tularik Inc. Isolated nucleic acids encoding CYP7 promoter-binding factors

Also Published As

Publication number Publication date
AU2003223208A1 (en) 2003-09-16
AU2003223208A8 (en) 2003-09-16
WO2003074663A2 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
WO2003083047A3 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003006614A3 (en) UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2004013309A3 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2004005483A3 (en) ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004005486A3 (en) Mp21s as modifiers of the p21 pathway and methods of use
WO2004015073A3 (en) MP21S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2003074663A3 (en) MP21s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004015069A3 (en) MP2153S AS MODIFIERS OF THE p21 OR p53 PATHWAY AND METHODS OF USE
WO2004013308A3 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074677A3 (en) MCHKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE
WO2003074673A3 (en) Lgals as modifiers of the chk pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005001026A3 (en) Adks as modifiers of the pten pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP